Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJul 26, 2026
DataAggregated Company Financials
Companies9
  • 7D3.4%
  • 3M9.7%
  • 1Y35.6%
  • YTD11.7%

The Pharma industry is up 3.4% in the last week, with Roche Holding up 6.3%. This means that the industry has gained 36% over the past year. Earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 26 Jul 2026CHF 597.9bCHF 123.3bCHF 24.1b35.6x24.8x4.8x
Tue, 23 Jun 2026CHF 550.4bCHF 122.9bCHF 25.1b38.2x21.9x4.5x
Thu, 21 May 2026CHF 560.3bCHF 121.3bCHF 24.8b39.6x22.6x4.6x
Sat, 18 Apr 2026CHF 555.2bCHF 121.0bCHF 25.1b40.1x22.1x4.6x
Mon, 16 Mar 2026CHF 554.6bCHF 121.7bCHF 25.2b37.1x22x4.6x
Wed, 11 Feb 2026CHF 580.4bCHF 119.1bCHF 24.2b38x24x4.9x
Fri, 09 Jan 2026CHF 579.7bCHF 121.4bCHF 21.6b36.3x26.9x4.8x
Sun, 07 Dec 2025CHF 541.5bCHF 121.7bCHF 21.6b33.9x25x4.4x
Tue, 04 Nov 2025CHF 479.1bCHF 121.9bCHF 21.7b32.5x22.1x3.9x
Thu, 02 Oct 2025CHF 500.4bCHF 120.2bCHF 20.9b32.2x23.9x4.2x
Sat, 30 Aug 2025CHF 479.3bCHF 120.4bCHF 21.0b30.4x22.9x4x
Mon, 28 Jul 2025CHF 460.3bCHF 119.9bCHF 20.7b23.3x22.2x3.8x
Wed, 25 Jun 2025CHF 446.9bCHF 117.8bCHF 19.0b25.2x23.5x3.8x
Fri, 23 May 2025CHF 435.8bCHF 119.4bCHF 19.3b24.9x22.6x3.7x
Sun, 20 Apr 2025CHF 413.0bCHF 117.3bCHF 18.4b24.6x22.4x3.5x
Tue, 18 Mar 2025CHF 485.8bCHF 121.5bCHF 19.1b29.9x25.4x4x
Thu, 13 Feb 2025CHF 478.1bCHF 123.3bCHF 19.3b22.9x24.8x3.9x
Sat, 11 Jan 2025CHF 444.2bCHF 120.1bCHF 21.5b18.5x20.6x3.7x
Mon, 09 Dec 2024CHF 428.1bCHF 117.7bCHF 21.1b18.3x20.3x3.6x
Wed, 06 Nov 2024CHF 445.6bCHF 116.7bCHF 20.9b19.3x21.3x3.8x
Fri, 04 Oct 2024CHF 446.9bCHF 115.1bCHF 19.3b21.3x23.1x3.9x
Sun, 01 Sep 2024CHF 478.3bCHF 114.9bCHF 19.3b22.8x24.8x4.2x
Tue, 30 Jul 2024CHF 465.1bCHF 116.9bCHF 19.7b22.2x23.6x4x
Thu, 27 Jun 2024CHF 434.1bCHF 116.3bCHF 19.8b33.9x22x3.7x
Sat, 25 May 2024CHF 409.2bCHF 117.4bCHF 19.9b42.1x20.5x3.5x
Mon, 22 Apr 2024CHF 398.4bCHF 112.4bCHF 19.5b36.9x20.5x3.5x
Wed, 20 Mar 2024CHF 387.5bCHF 111.2bCHF 19.3b37.3x20.1x3.5x
Fri, 16 Feb 2024CHF 378.6bCHF 110.3bCHF 19.7b23.8x19.2x3.4x
Sun, 14 Jan 2024CHF 415.7bCHF 119.4bCHF 18.7b27.1x22.3x3.5x
Tue, 12 Dec 2023CHF 404.1bCHF 121.2bCHF 18.9b24.5x21.4x3.3x
Thu, 09 Nov 2023CHF 388.1bCHF 122.3bCHF 19.1b23.8x20.4x3.2x
Sat, 07 Oct 2023CHF 405.3bCHF 113.3bCHF 18.1b42.2x22.4x3.6x
Mon, 04 Sep 2023CHF 405.5bCHF 112.1bCHF 18.0b48.3x22.6x3.6x
Wed, 02 Aug 2023CHF 418.1bCHF 114.8bCHF 19.3b48.6x21.7x3.6x
Price to Earnings Ratio

21.7x


Total Market Cap: CHF 418.1bTotal Earnings: CHF 19.3bTotal Revenue: CHF 114.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are optimistic on the Swiss Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 24.8x which is higher than its 3-year average PE of 22.5x.
  • The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 7.7% per year over the last three years.
  • Revenues for these companies have grown 2.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market-0.43%
Healthcare2.50%
Pharma3.40%
Pharma3.40%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROP Roche HoldingCHF 355.106.3%
+CHF 17.0b		37.0%PE22.9x
NOVN NovartisCHF 126.901.5%
+CHF 12.4b		36.7%PE23.1x
GALD Galderma GroupCHF 173.650.7%
+CHF 269.8m		29.1%PE81.2x
NWRN Newron PharmaceuticalsCHF 11.882.6%
+CHF 6.2m		68.8%PS13.9x
COPN CosmoCHF 63.600.3%
+CHF 3.2m		1.3%PS10.8x

Latest News

ROP
CHF 355.10
Roche Holding
7D
6.3%
1Y
37.0%
COPN
CHF 63.60
Cosmo
7D
0.3%
1Y
1.3%
Narrative Update • Jul 24

COPN: Higher Projected Margins And P/E Will Support Future Upside Potential

Analysts have trimmed their fair value estimate for Cosmo from CHF 100.28 to CHF 92.09. This reflects updated assumptions for revenue growth, profit margins and future P/E expectations.
NOVN
CHF 126.90
Novartis
7D
1.5%
1Y
36.7%
Analysis Article • Jul 24

Revenue Beat: Novartis AG Beat Analyst Estimates By 5.7%

It's been a good week for Novartis AG ( VTX:NOVN ) shareholders, because the company has just released its latest...
GALD
CHF 173.65
Galderma Group
7D
0.7%
1Y
29.1%
SDZ
CHF 63.62
Sandoz Group
7D
-3.2%
1Y
35.1%
ADXN
CHF 0.043
Addex Therapeutics
7D
7.5%
1Y
-27.4%
CURN
CHF 23.50
Curatis Holding
7D
2.6%
1Y
113.6%
NWRN
CHF 11.88
Newron Pharmaceuticals
7D
2.6%
1Y
68.8%
New Narrative • May 10

Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
BIOV
CHF 27.30
BioVersys
7D
1.5%
1Y
-19.7%